Tumor-infiltrating lymphocytes predict survival in ≥ pT2 urothelial bladder cancer.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 26 05 2022
accepted: 20 07 2022
pubmed: 1 8 2022
medline: 26 10 2022
entrez: 31 7 2022
Statut: ppublish

Résumé

Tumor-infiltrating lymphocytes (TILs) are associated with improved survival in several types of cancers, including genitourinary cancers. However, multiple different scoring methods used to assess TILs complicate the comparison of different studies and are not always suitable for daily practice. In 2014, the International TILs Working Group (ITWG) proposed a simple and robust assessment method for a more standardized evaluation of TILs. Here, we validated this system in muscle-invasive urinary bladder cancer (MIBC). Patient history and histologic specimens from 203 patients with MIBC were retrospectively analyzed. The stromal TIL (sTIL) score was determined using the ITWG system and 3 groups were defined according to the degree of stromal lymphocytic infiltration: low (0-10%), intermediate (10-55%) and high (55-100%). Associations between sTIL score, clinicopathological variables, tumor-specific survival (TSS), overall survival (OS), and disease-free survival (DFS) were analyzed. High stromal lymphocytic infiltration was associated with significantly higher OS, TSS and DFS when compared to low grade sTILs. The survival benefit remained statistically significant in multivariate analyses, confirming that sTILs are a strong independent positive prognostic factor in patients with MIBC. In summary, the degree of sTILs as defined by the ITWG robustly predicts survival in MIBC patients. Prospective studies with larger case numbers are needed to determine whether sTILs should be included in staging guidelines and how they could aid in therapeutic decision making.

Identifiants

pubmed: 35908386
pii: S0344-0338(22)00281-3
doi: 10.1016/j.prp.2022.154037
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

154037

Informations de copyright

Copyright © 2022 Elsevier GmbH. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of interest None.

Auteurs

Stephan Ledderose (S)

Department of Pathology, Ludwig Maximilian University Munich, Germany. Electronic address: stephan.ledderose@med.uni-muenchen.de.

Severin Rodler (S)

Department of Urology, Ludwig Maximilian University Munich, Germany.

Lennert Eismann (L)

Department of Urology, Ludwig Maximilian University Munich, Germany.

Georg Ledderose (G)

Department of Oto-Rhino-Laryngology, Ludwig Maximilian University Munich, Germany.

Carola Ledderose (C)

Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH